Boston Scientific (BSX) Capital Expenditures (2009 - 2026)

Boston Scientific (BSX) has 18 years of Capital Expenditures data on file, last reported at $177.0 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures fell 5.35% year-over-year to $177.0 million; the trailing twelve-month figure through Mar 2026 stood at $866.0 million (up 8.52% YoY), and the FY2025 full-year result was $876.0 million, up 10.89% from the prior year.
• Capital Expenditures retreated to $177.0 million in Q1 2026, from $351.0 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $351.0 million in Q4 2025 to a low of $105.0 million in Q2 2022.
• A 5-year average of $184.8 million and a median of $179.0 million in 2024 frame the typical range for Capital Expenditures.
• Peak annual rise in Capital Expenditures reached 61.33% in 2022, while the deepest fall reached 20.3% in 2022.
• Tracing BSX's Capital Expenditures over 5 years: stood at $212.0 million in 2022, then rose by 25.94% to $267.0 million in 2023, then gained by 3.75% to $277.0 million in 2024, then advanced by 26.71% to $351.0 million in 2025, then tumbled by 49.57% to $177.0 million in 2026.
• Business Quant data shows BSX's Capital Expenditures at $177.0 million in Q1 2026, $351.0 million in Q4 2025, and $181.0 million in Q3 2025.